Previous 10 | Next 10 |
IDEAYA Biosciences (NASDAQ:IDYA): Q3 GAAP EPS of -$0.31 beats by $0.01. Revenue of $8.97M (-0.2% Y/Y) beats by $0.42M. Press Release For further details see: IDEAYA Biosciences EPS beats by $0.01, beats on revenue
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Observed IDE397 preliminary clini...
IDEAYA Biosciences to Participate in Investor Conferences in November 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company commi...
IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer - Former Chief Scientific Officer and Head of Tumor Biology at Pfizer will lead IDEAYA's research organization as Chief Scientific Officer - Over twenty-year academic career at UT Southwestern and ...
After an all-time high on Wednesday, IDEAYA Biosciences (IDYA -12.7%) has shed more than a tenth of the market cap to record the biggest intraday loss since early July after Stifel started the coverage of the stock with a hold rating. Estimating a price target of $27 per share, the analyst Be...
IDEAYA Biosciences to Participate in Investor Conferences in September 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company co...
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 - Enrolling MTAP-deletion solid tu...
IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 2, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-fo...
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif. , July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today anno...
IDEAYA Biosciences (IDYA) has priced its public offering of 4,637,681 common shares at $17.25/share, for expected gross proceeds of ~$80M.Underwriters' over-allotment is an additional 695,652 shares. Net proceeds will be used to fund preclinical and clinical development of product candid...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...